Vergoeding 2017-2021 voor ATC-subgroep V03AE : Middelen bij hyperkaliemie en hyperfosfatemie
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| V03AE01 Polystyreensulfonzuur (na-zout ca-zout) (Resonium a ®) | 1.689.400 | 1.689.400 | 1.639.600 | 1.591.400 | 1.549.900 |
| V03AE02 Sevelameer (Renagel ®) | 4.923.400 | 3.692.500 | 2.956.700 | 2.793.400 | 2.354.600 |
| V03AE03 Lanthaancarbonaat (Fosrenol ®) | 3.333.200 | 3.270.000 | 3.653.400 | 3.673.900 | 3.455.600 |
| V03AE04 Calciumacetaat met magnesiumcarbonaat (Osvaren ®) | 62.881 | 58.631 | 77.003 | 80.856 | 77.742 |
| V03AE05 Ferrioxyhydroxide-sucrose-complex (Velphoro ®) | 402.130 | 564.900 | 591.810 | 574.380 | 562.000 |
| V03AE07 Calciumacetaat | . | . | 279 | 3.988 | 4.822 |
| V03AE09 Patiromeer calcium (Veltassa ®) | . | . | 15.752 | 114.130 | 228.480 |
| V03AE10 Natriumzirconiumcyclosilicaat (Lokelma ®) | . | . | . | . | 102.790 |
| Totaal | 10.411.011 | 9.275.431 | 8.934.544 | 8.832.054 | 8.335.934 |